HCA Healthcare, Inc.

(New York Stock Exchange)
Back to all articles
Bullish +75

HCA Healthcare Q1 2026 Revenue Up 4.3%

AI-generated analysis

πŸ“ˆ HCA Healthcare reported Q1 2026 revenue of $19.109 billion, representing a 4.3% increase from the prior year.

πŸ’° Net income attributable to the company reached $1.620 billion, an increase from $1.610 billion in the same quarter last year.

πŸ“Š Diluted earnings per share rose 10.9% to $7.15, compared to $6.45 a year ago.

πŸš€ Adjusted EBITDA grew by 1.9% to $3.802 billion, while cash flow from operating activities surged 22.0%.

πŸ₯ Same-facility admissions increased 0.9%, and same-facility equivalent admissions rose 1.3% during the quarter.

⚠️ Procedure volumes showed weakness with inpatient surgeries down 0.3% and outpatient surgeries falling 1.7%.

πŸ’¨ Respiratory-related admissions fell sharply by 42%, and respiratory ER visits declined 32% from the previous year.

🌨️ Volume pressures were partly attributed to a January winter storm affecting some markets and reduced respiratory demand.

βš–οΈ Higher revenue per equivalent admission of 3.1% helped offset volume declines in procedure areas.

πŸ’΅ HCA held $940 million in cash, with $48.023 billion in total debt and $61.450 billion in total assets at March 31.

πŸ—οΈ Capital expenditures for the quarter totaled $1.119 billion, excluding any acquisitions made during the period.

πŸ”„ The company repurchased 3.157 million shares for $1.571 billion with approximately $9.179 billion remaining in authorization.

πŸ’° A quarterly dividend of $0.78 per share was declared, payable on June 30 to shareholders of record June 16.

πŸ“‰ Shares dropped -0.76% to $480.32 following the earnings announcement and other financial disclosures.

Bullish Signals
  • HCA Healthcare reported first-quarter 2026 revenue of $19.109 billion, representing a 4.3% year-over-year increase.
  • Net income attributable to the company rose to $1.620 billion from $1.610 billion, while diluted earnings per share increased 10.9% to $7.15.
  • Cash flow from operating activities jumped 22.0% to $2.014 billion, demonstrating strong liquidity generation.
  • The company successfully repurchased 3.157 million shares for $1.571 billion, leaving $9.179 billion remaining under its buyback authorization.
  • At March 31, HCA held $940 million in cash and cash equivalents, providing a robust financial buffer.
  • The board declared a quarterly dividend of $0.78 per share, payable to shareholders of record on June 16.
  • Revenue per equivalent admission increased 3.1% from the prior-year quarter, indicating strong pricing power or mix improvement.
Risk Factors
  • The market reacted negatively to these announcements, causing shares to decline 0.76% to a price of $480.32.
  • Procedure volumes weakened significantly, with same-facility inpatient surgeries slipping 0.3% and outpatient surgeries falling 1.7%.
  • Significant volume pressures were experienced as respiratory-related admissions fell 42% and respiratory-related emergency room visits declined 32% versus the first quarter of 2025.
  • A January winter storm weighed on volumes in some markets, further suppressing operational metrics.
  • While revenue per admission increased, it was partly offset by recognizing Medicaid supplemental programs not included in initial 2026 guidance, suggesting reliance on non-core revenue streams to meet targets.
  • The company held $48.023 billion in total debt against only $940 million in cash and cash equivalents as of March 31, indicating a high leverage position.
Full Analysis
HCA Healthcare reported robust financial results for the first quarter of 2026, with revenue reaching $19.109 billion, representing a 4.3% increase from the same period last year. Net income attributable to the company grew to $1.620 billion, while diluted earnings per share rose significantly by 10.9% to $7.15. Adjusted EBITDA increased modestly by 1.9% to $3.802 billion, and cash flow from operating activities saw a substantial jump of 22.0% to $2.014 billion. Despite these overall gains, procedure volumes showed weakness with inpatient surgeries down slightly and outpatient surgeries falling 1.7%. Operational volumes faced specific headwinds due to external factors, with respiratory-related admissions dropping 42% and emergency room visits for similar issues declining 32%, partly attributed to a January winter storm affecting some markets. However, the company offset some of this volume pressure by recognizing Medicaid supplemental programs not included in its initial guidance. Revenue per equivalent admission improved by 3.1%, indicating successful price or mix strategies despite lower admission volumes in certain categories. Regarding capital management and shareholder returns, HCA ended the quarter with $940 million in cash and debt levels stood at $48.023 billion against total assets of $61.450 billion. The company invested $1.119 billion in capital expenditures excluding acquisitions and utilized $1.571 billion for share repurchases, leaving $9.179 billion remaining under its buyback authorization. Additionally, HCA maintains $4.336 billion of availability under its credit facility and declared a quarterly dividend of $0.78 per share, payable on June 30 to shareholders of record as of June 16.